Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based medical research and telemedicine company with a clinic that provide ketamine treatments for persons with depression and related disorders. Through its medical solutions, it intends to reduce the illness burden of brain-based disorders, such as major depressive disorder, among others. The Company is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. It seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. The Company has clinic operations in the Canadian cities of Mississauga, Kitchener-Waterloo, Ottawa and Montreal. Its subsidiary, Braxia Health, is engaged in offering rapid onset treatments to aid those suffering from several treatment-resistant conditions, such as depression and bipolar disorder.


CSE:BRAX - Post by User

Bullboard Posts
Post by cautiousguyon Jun 22, 2020 7:36pm
337 Views
Post# 31178791

Here is a news release from Stockwatch

Here is a news release from Stockwatch
Champignon Brands Inc
Symbol SHRM
Shares Issued 177,290,212
Close 2020-06-19 C$ 0.89
Recent Sedar Documents

 

Champignon under BCSC microscope over disclosures

2020-06-22 12:44 ET - News Release

Dr. Roger McIntyre reports

CHAMPIGNON ANNOUNCES REGULATORY REVIEW

Champignon Brands Inc. has been selected for a continuous disclosure review by the British Columbia Securities Commission. The review relates to the company's disclosure obligations since it became a reporting issuer on Feb. 6, 2020, and includes a review of the disclosure surrounding certain recent acquisitions completed by the company.

"With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention. Ensuring fulsome and timely disclosure is vital to the success of our company and development of our industry with the investing public. We look forward to working with staff of the British Columbia Securities Commission to complete their review and are hopeful that trading will resume as soon as possible," commented Dr. Roger McIntyre, chief executive officer of the company.

In connection with the review, the commission has issued a cease trade order suspending trading in the securities of the company, pending the filing of business acquisition reports by the company in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. As a result of the cease trade order, trading in the common shares of the company has been suspended on the Canadian Securities Exchange.

The company will fully co-operate with the commission to assist in completion of the review and revocation of the cease trade order in a timely fashion. The company will provide further information regarding the status of the review and the suspension of trading as it becomes available.

We seek Safe Harbor.


Bullboard Posts